4 ms·

Kyverna claims to have achieved remission in clinical trials. Is that really a nothing burger? https://lupus.bmj.com/content/11/Suppl_1/A109 https://lupus.bmj.

• randycupertino 11mo ago
  I'm not saying Car-T doesn't work for certain diseases, more that it's too complex and too expensive to operationalize and unsustainable to bring to mass-market. It may prove successful as a one-off for individual rich single-payer patients but cell therapy companies fail left and right because they repeatedly can't operationalize the treatment into a sustainable business model. It has promising data and potential for transformational results, sure just too many challenges exist thus far for anyone to demonstrate durability bringing an actual treatment to market without major technological and economic advancements. The infrastructure & manufacturing is too intense, it's just not a scalable business.